公开(公告)号：US20060252930A1

公开(公告)日：2006-11-09

申请号：US10548452

申请日：2003-08-29

申请人： Satoshi Omura ,  Hiroshi Tomoda ,  Rokura Masuma ,  Masayoshi Arai

发明人： Satoshi Omura ,  Hiroshi Tomoda ,  Rokura Masuma ,  Masayoshi Arai

IPC分类号： C07D267/22 ,  C07K7/60

CPC分类号： C12P17/14 ,  A61K31/395 ,  C07D273/00 ,  C12R1/645

摘要： A microorganism belonging to Beauveria sp. and having ability to produce FKI-1366 substance A and/or FKI-1366 substance B and/or FKI-1366 substance C (Beauveria sp. FKI-1366 FERM BP-08459) is cultured in a medium, accumulating FKI-1366 substance A and/or FKI-1366 substance B and/or FKI-1366 substance C in the culture liquid and isolating FKI-1366 substance A and/or FKI-1366 substance B and/or FKI-1366 substance C from the cultured mass. Since the thus obtained FKI-1366 substance A and/or FKI-1366 substance B and/or FKI-1366 substance C or composition thereof have activity to enhance azole antifungal agent, the substance has an action against various fungal infections such as deep-seated mycosis and other fungal infections in the low concentration within short term. Consequently, the substance is useful for reducing frequency of appearance of resistant microorganisms and overcoming resistance, and is expected as a medicament.

摘要翻译： 属于白僵菌的微生物 并且在培养基中培养产生FKI-1366物质A和/或FKI-1366物质B和/或FKI-1366物质C（白僵菌FKI-1366FERM BP-08459）的能力，将FKI-1366物质A 和/或FKI-1366物质B和/或FKI-1366物质C，并从培养物质中分离FKI-1366物质A和/或FKI-1366物质B和/或FKI-1366物质C。 由于如此获得的FKI-1366物质A和/或FKI-1366物质B和/或FKI-1366物质C或其组合物具有增强唑类抗真菌剂的活性，所以该物质具有针对各种真菌感染的作用，例如深层 短期内低浓度的真菌病和其他真菌感染。 因此，该物质可用于降低抗性微生物的出现频率并克服抗性，并且预期作为药物。